Holen Sie sich die Stockscreener-App
3.355
1.32%
-0.045
Schlusskurs vom Vortag:
$3.40
Offen:
$3.38
24-Stunden-Volumen:
24,167
Relative Volume:
0.10
Marktkapitalisierung:
$136.07M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-58.75M
KGV:
-0.7754
EPS:
-4.327
Netto-Cashflow:
$-50.79M
1W Leistung:
-5.23%
1M Leistung:
-18.96%
6M Leistung:
-1.32%
1J Leistung:
+30.54%
1-Tages-Spanne:
$3.319
$3.4899
1-Wochen-Bereich:
$3.319
$3.90
52-Wochen-Spanne:
$2.23
$5.38
Onkure Therapeutics Inc Stock (OKUR) Company Profile
Firmenname
Onkure Therapeutics Inc
Sektor
Branche
Telefon
(720) 307-2892
Adresse
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Compare OKUR vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
3.36 | 137.69M | 0 | -58.75M | -50.79M | -4.327 |
VRTX
Vertex Pharmaceuticals Inc
|
522.70 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.30 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.25 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.40 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.33 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-30 | Eingeleitet | Evercore ISI | Outperform |
| 2024-12-05 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-10 | Eingeleitet | Oppenheimer | Outperform |
| 2023-12-15 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-12-15 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-15 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-12-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-12-14 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2023-12-14 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-12-14 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-12-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-11-15 | Eingeleitet | William Blair | Outperform |
| 2023-08-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-07-03 | Eingeleitet | BofA Securities | Buy |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-01-27 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-12-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-22 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2021-05-04 | Eingeleitet | Jefferies | Buy |
| 2021-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2021-05-04 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Onkure Therapeutics Inc Aktie (OKUR) Neueste Nachrichten
OnKure management will hold one-on-one investor meetings in New York - Stock Titan
OnKure (OKUR) Session: Ends Up by 0.25% at $3.94 in the Latest Reading; Key Range: Traders Can Monitor the $3.74-$4.14 Range in Latest TradingChannel Projection - vinanet.vn
Prosight Management, LP Reduces OnKure Therapeutics (OKUR) Stake in Second Quarter - GuruFocus
OnKure Therapeutics (OKUR): ADAR1 reports 5.5% stake as GP falls below 5% - Stock Titan
OnKure Therapeutics (OKUR) investor BVF discloses 8% stake plus 2.15M pre-funded warrants - Stock Titan
OnKure Therapeutics (OKUR) sees 3.6% passive stake reported by Trails Edge - Stock Titan
Oppenheimer Adjusts OnKure Therapeutics PT to $14 From $30, Maintains Outperform Rating - marketscreener.com
OKUR Q2 2026 Earnings: Narrower-Than-Expected Loss Points to Cost Discipline at Clinical-Stage BiotechEstimate Dispersion - vinanet.vn
OKUR Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates by 43.19%Revenue Recognition Risk - Vinanet
OnKure Reprices Underwater Stock Options to Boost Retention - TipRanks
Prosight entities report 2.4% OnKure Therapeutics (OKUR) stake in 13G/A - Stock Titan
OnKure Therapeutics (OKUR) Holds Steady at $4.14 as Biotech Consolidates Within Tight RangeEarnings Sentiment - dars.gov.et
Onkure Therapeutics Inc (OKUR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
LifeSci Capital Maintains OnKure Therapeutics(OKUR.US) With Buy Rating, Maintains Target Price $16 - Moomoo
OnKure Therapeutics has cash runway into 2029 - BizWest
JonesTrading Maintains OnKure Therapeutics(OKUR.US) With Hold Rating - Moomoo
OnKure Therapeutics reports Q2 2026 net loss $15.3M; $176.4M cash runway into 2029 - TradingView
OKUR: IND-enabling PI3Ka programs advance toward 2027 filings, backed by $176M cash runway into 2029 - TradingView
OnKure Therapeutics, Inc. Q2 2026: Net loss $(30.5M) for 6M, EPS $(0.31) — 10-Q Summary - TradingView
OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights - The Manila Times
OnKure Therapeutics (Nasdaq: OKUR) raises $150M to fund PI3Kα drugs - Stock Titan
OKUR: Q2 2026 net loss was $15.3M; cash reserves strengthened by $150M private placement - TradingView
OnKure Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
OnKure Therapeutics Rings the Closing Bell - Nasdaq
OnKure Therapeutics Rings the Nasdaq Stock Market Closing Bell - Nasdaq
OnKure Therapeutics, Inc. Revenue Breakdown – NASDAQ:OKUR - TradingView
OnKure Therapeutics (OKUR) Falls 4.5% to $3.82: Support at $3.63 Faces Key TestLast Point Support - vinanet.vn
Vivo Capital LLC Invests $7.98 Million in OnKure Therapeutics, Inc. $OKUR - MarketBeat
Onkure Therapeutics Inc (OKUR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Onkure Therapeutics Inc (OKUR) Balance Sheet - TradingKey
Onkure Therapeutics Inc (OKUR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
OKUR|Onkure Therapeutics Inc|Price:4.050|Chg%:-0.070 - TradingKey
Onkure Therapeutics Inc (OKUR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
OnKure Therapeutics (OKUR) Slips 1.7% as Shares Test Key Support ZoneEMA Signal - vinanet.vn
Onkure Therapeutics Inc (OKUR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Onkure Therapeutics Inc (OKUR) Institutional Confidence - TradingKey
Onkure Therapeutics Inc (OKUR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Onkure Therapeutics Inc (OKUR) Cash Flow - TradingKey
Onkure Therapeutics Inc (OKUR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
OKUR Q1 2026 Earnings: Wider-than-expected loss as clinical-stage biotech progresses pipelineBanking Earnings Report - vinanet.vn
Onkure Therapeutics Inc (OKUR) Income Statement - TradingKey
OKUR Options Volatility — NASDAQ:OKUR - TradingView
OKUR Options Chain — NASDAQ:OKUR - TradingView
Price to earnings forward of OnKure Therapeutics, Inc. – NASDAQ:OKUR - TradingView
OnKure Therapeutics (OKUR) Rises 3.6% as Stock Approaches Key Resistance LevelBPI Bear Correction - vinanet.vn
Price to sales forward of OnKure Therapeutics, Inc. – NASDAQ:OKUR - TradingView
H.C. Wainwright cuts OnKure stock price target to $21 on valuation changes - Investing.com
OKUR Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
OnKure Therapeutics Price Target Cut to $21.00/Share From $27.00 by HC Wainwright & Co. - Moomoo
H.C. Wainwright Maintains OnKure Therapeutics(OKUR.US) With Buy Rating, Cuts Target Price to $21 - Moomoo
OnKure Therapeutics Inc. (OKUR) Q1 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Advances PipelineEarnings Revision Upgrade - vinanet.vn
Finanzdaten der Onkure Therapeutics Inc-Aktie (OKUR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Onkure Therapeutics Inc-Aktie (OKUR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Leverone Jason A. | Chief Financial Officer |
Jun 22 '26 |
Sale |
4.40 |
303 |
1,332 |
18,802 |
| Saccomano Nicholas A | President and CEO |
Mar 23 '26 |
Sale |
4.16 |
86 |
357 |
7,333 |
| Leverone Jason A. | Chief Financial Officer |
Mar 23 '26 |
Sale |
4.16 |
301 |
1,251 |
16,000 |
| Saccomano Nicholas A | President and CEO |
Dec 22 '25 |
Sale |
2.97 |
87 |
258 |
7,419 |
| Leverone Jason A. | Chief Financial Officer |
Dec 22 '25 |
Sale |
2.97 |
302 |
896 |
16,301 |
| Saccomano Nicholas A | President and CEO |
Sep 22 '25 |
Sale |
2.62 |
88 |
231 |
3,506 |
| Leverone Jason A. | Chief Financial Officer |
Sep 22 '25 |
Sale |
2.62 |
303 |
795 |
12,603 |
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):